NCT06536244

Brief Summary

The relationship between perioperative drugs, including preoperative medications, anesthetics, and analgesics, and postoperative outcomes in cancer patients is a complex and evolving field of study. Understanding how those medications might impact outcomes such as pain, acute kidney injury, and recurrence is crucial for optimizing perioperative care in renal cancer patients.

Trial Health

50
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
25mo left

Started Jul 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress75%
Jul 2020Sep 2028

Study Start

First participant enrolled

July 31, 2020

Completed
4 years until next milestone

First Submitted

Initial submission to the registry

July 23, 2024

Completed
10 days until next milestone

First Posted

Study publicly available on registry

August 2, 2024

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2026

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2028

Last Updated

August 2, 2024

Status Verified

July 1, 2024

Enrollment Period

6.1 years

First QC Date

July 23, 2024

Last Update Submit

July 31, 2024

Conditions

Perioperative AnestheticRenal Cancer

Outcome Measures

Primary Outcomes (1)

  • Postoperative complications

    72 hours and 30 days postoperatively

Secondary Outcomes (1)

  • Overall survival

    Recurrence-free survival:The length of time from surgery to last seen without recurrence or with recurrent disease.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

MD Anderson Cancer Center

You may qualify if:

  • Adult Participants (18 years of age or older)
  • Participants having radical or partial nephrectomies with curative intent.

You may not qualify if:

  • Patients with distant metastatic disease and those with multiple (more than 1) primary tumors at the time of the nephrectomy
  • Biopsies
  • Participants who had radiofrequency or microwave ablations.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Links

MeSH Terms

Conditions

Kidney Neoplasms

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital Diseases

Study Officials

  • Juan P Cata, MD

    M.D. Anderson Cancer Center

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 23, 2024

First Posted

August 2, 2024

Study Start

July 31, 2020

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

September 1, 2028

Last Updated

August 2, 2024

Record last verified: 2024-07

Locations

US(1)